… -regional radiotherapy, and systemic therapy. Besides conventional chemotherapy, multi
kinase-targeted inhibitors are emerging as novel therapeutic tools. The numerous molecular …

… of thyroid cancer treatment. Although TKIs are promising agents for thyroid cancer treatment,
… Thus, even in the TKI era, a multimodal treatment including surgery, radioiodine therapy, …

… Systemic chemotherapies for advanced or metastatic thyroid carcinomas have been of only
limited effectiveness. For patients with differentiated or medullary carcinomas unresponsive …

… in the systemic therapies of metastatic thyroid cancers are … of systemic therapies in metastatic
thyroid cancer patients. … retrospectively, diagnosed with thyroid cancer who were referred to …

… therapeutic target, resistant disease can develop in the face of RET-targeting tyrosine kinase
inhibitors (TKIs) and options for systemic therapy of … targets for the systemic therapy of MTC …

… thyroid cancer; in this review, we discuss these needs and our suggestions based on our
recent research on thyroid cancer. … and safety of the available systemic therapeutic agents, it is …

… Background: With the emergence of mutation-based systemic therapies for patients with
advanced thyroid cancer, molecular profiling has become an important component of care. …

… In comparison, SAE frequency in other established systemic therapies for thyroid cancer
have ranged from 0.4% to as high as 47% (Table 2), which further highlights the relatively better …

… Furthermore, the measurement of serum calcitonin is also valuable in metastatic MTC to
evaluate the response to systemic therapy [105]. MTC also secretes carcinoembryonic antigen (…

… Since the most eÄective systemic therapy for diÄerentiated thyroid cancer has been
radioiodine, it is rational to attempt to restore the components of iodide uptake and retention which …